Canada's LSL Pharma Q2 revenue surges on acquisition boost, eye-drop launches

LSL Pharma

25/08/2026 13:30

Overview
Canada pharmaceutical maker's fiscal Q2 revenue more than doubled yr/yr to record high
Company posted wider net loss, impacted by higher costs and Steri-Med production slowdown
Growth driven by acquisitions and eye-drop launches; expects further gains as remediation ends

Outlook
Company expects Steri-Med to deliver revenue growth in H2 2026
LSL Pharma plans to launch three additional ophthalmic drops in H2 2026
Company expects Health Canada remediation plan to be substantially completed by end-2026

Result Drivers
ACQUISITIONS - Revenue growth attributed mainly to addition of Du-Var and LSL MedPlus, per company
NEW PRODUCT LAUNCHES - Commercial launch of new eye-drops contributed to record revenues, per CEO François Roberge
PRODUCTION SLOWDOWN - Gross profit and net loss impacted by Steri-Med production halt/slowdown due to Health Canada remediation plan

Company press release: ID:nCNW7brVQa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
C$14.6 mln
 

Reuters Recommended Reads
Aug 24 - Canada's Nanalysis Q2 revenue edges up on services strength
Aug 24 - China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Aug 24 - China's InnoCare Pharma H1 revenue surges, partly on orelabrutinib growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)